Results 171 to 180 of about 26,436 (212)

Strategic driving of the cancer-immunity cycle in HCC: roles of immune, molecular-targeted, and locoregional therapies. [PDF]

J Liver Cancer
Iwamoto H, Koga H, Kawaguchi T.
europepmc   +1 more source

HAIC combined with atezolizumab and bevacizumab versus lenvatinib in advanced hepatocellular carcinoma: a multicenter propensity score matching analysis. [PDF]

Front Oncol
Zhao L, Liu D, Ma C, Hu Y, Liu S.
europepmc   +1 more source

A 73-Year-Old Man With a Late Isolated Brain Metastasis of Clear Cell Renal Cell Carcinoma Following a Durable Complete Response to Lenvatinib-Pembrolizumab, Resulting in Deferred Cytoreductive Nephrectomy. [PDF]

Am J Case Rep
Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T.   +4 more
europepmc   +1 more source

Lenvatinib-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Metastatic Clear Cell Renal Cell Carcinoma: A Case Report. [PDF]

Cureus
Luginaah NA, Climans S, Akingbade A.
europepmc   +1 more source

Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment.

J Clin Endocrinol Metab
Minaldi E, Ramone T, Ciampi R, Romei C, Casalini R, Gambale C, Prete A, Lorusso L, Agate L, Torregrossa L, Piaggi P, Matrone A, Elisei R.   +12 more
europepmc   +1 more source

COLEC12high tumor-associated macrophages: A novel paracrine axis driving lenvatinib resistance in hepatocellular carcinoma: Editorial on "COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling". [PDF]

Clin Mol Hepatol
Han JW.
europepmc   +1 more source

GLP-1 receptor agonist targets an AMPKα1-HIF1α-PFKFB3 metabolic vulnerability and enhances Lenvatinib response in hepatocellular carcinoma. [PDF]

NPJ Precis Oncol
Noma T, Li Y, Wada Y, Morine Y, Ikemoto T, Saito Y, Shimada M, Goel A.   +7 more
europepmc   +1 more source